{
  "id": 2889476,
  "title": "Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?",
  "url": "https://urgent.news/2026/08/23/johnson-johnson-vs-thermo-fisher-which-healthcare-growth-story-is",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-23T22:32:03.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-thermo-fisher-223203633.html"
  },
  "original_language": "en",
  "account": "For healthcare investors seeking long-term growth, the choice between Johnson & Johnson (NYSE:JNJ) and Thermo Fisher (NYSE:TMO) is not a simple one. Both companies demonstrate strong fundamentals, but their growth trajectories differ significantly. Johnson & Johnson (NYSE:JNJ) benefits from a well-rounded portfolio, with pharmaceuticals, medical technology, and a robust pipeline driving revenue. Despite a 55% drop in Stelara sales due to a patent loss, their Tremfya drug and other immunology products have more than made up for the decline. Thermo Fisher (NYSE:TMO), on the other hand, relies heavily on life sciences industry growth and has seen a rebound in its Analytical Instruments segment. While its Life Sciences Solutions and bioproduction businesses have shown positive signs, organic revenue remains below its historic double-digit growth rates. Both companies face risks: Johnson & Johnson (NYSE:JNJ) may struggle with a slow return to its MedTech growth, while Thermo Fisher (NYSE:TMO) must prove that the current life sciences spending recovery is sustainable. Ultimately, Johnson & Johnson (NYSE:JNJ) offers greater resilience in case industry conditions worsen, but Thermo Fisher (NYSE:TMO) could provide cyclical upside if the life sciences sector continues to improve.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}